Metraipolis › archive › dc_c2fc6bf03958
Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS… — Europe PMC PMID:41630997
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41630997
- DOI
- 10.1016/j.xkme.2025.101198
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T18:51:38.128Z
- SHA-256 of the archived text
20dbe9aaa4fd7d7580b6340d74c44591c45a8af3beae06ed6ef9ab054be3cce6- Stable URL of this page
https://metraipolis.com/documento/dc_c2fc6bf03958
How to cite
Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS… — Europe PMC PMID:41630997 — Europe PMC (en), https://europepmc.org/article/MED/41630997 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c2fc6bf03958 (Metraipolis archive dc_c2fc6bf03958, sha256 20dbe9aaa4fd7d7580b6340d74c44591c45a8af3beae06ed6ef9ab054be3cce6)
BibTeX
@misc{dcc2fc6bf03958,
title = {Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS… — Europe PMC PMID:41630997},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41630997},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c2fc6bf03958; sha256 20dbe9aaa4fd7d7580b6340d74c44591c45a8af3beae06ed6ef9ab054be3cce6},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41630997. Agents can read the archived copy with the MCP tool read_document.